


BMJ Open R_xIALTA: evaluating the effect of a pharmacist-led intervention on CV risk in patients with chronic inflammatory diseases in a community pharmacy setting: a prospective pre-post intervention study

Yazid N Al Hamarneh ¹, Carlo Marra,² Robert Gniadecki,³ Stephanie Keeling,⁴ Andrea Morgan,⁵ Ross Tsuyuki⁶

To cite: Al Hamarneh YN, Marra C, Gniadecki R, *et al.* R_xIALTA: evaluating the effect of a pharmacist-led intervention on CV risk in patients with chronic inflammatory diseases in a community pharmacy setting: a prospective pre-post intervention study. *BMJ Open* 2021;**11**:e043612. doi:10.1136/bmjopen-2020-043612

► Prepublication history for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2020-043612>).

Received 11 August 2020
Revised 16 February 2021
Accepted 26 February 2021



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Yazid N Al Hamarneh;
Yazid.ALHamarneh@ualberta.ca

ABSTRACT

Patients with inflammatory conditions are at high risk for cardiovascular (CV) disease. Despite such elevated risk, their CV risk factors are suboptimally managed.

Objective To evaluate the effect of a pharmacist-led intervention on CV risk in patients with inflammatory conditions.

Methods

Design Prospective pre-postintervention.

Setting 17 community pharmacies across Alberta.

Population Adults with inflammatory conditions (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, gout, systemic lupus erythematosus, psoriasis vulgaris) who had at least one uncontrolled risk factor (A1C, blood pressure, LDL-cholesterol or current tobacco users).

Intervention All patients enrolled in the study received: physical and laboratory assessment, individualised CV risk assessment and education regarding this risk, treatment recommendations, prescription adaptation and prescribing where necessary to meet treatment targets, regular communication with the patient's treating physician(s) and regular follow-up with all patients every month for 6 months.

Outcomes Primary: change in estimated CV risk (risk of a major CV event in the next 10 years) after 6 months. Secondary: change in individual risk factors (blood pressure, LDL-cholesterol, A1C and tobacco cessation) over a 6-month period.

Results We enrolled 99 patients. The median age was 66.41 years (IQR 57.64–72.79). More than half of them (61%) were female and more than three-quarters (86%) were Caucasians. After adjusting for age, sex and ethnicity and centre effect, there was a reduction of 24.5% in CV risk ($p<0.001$); including a reduction of 0.3 mmol/L in LDL-c ($p<0.001$), 10.7 mm Hg in systolic blood pressure ($p<0.001$), 1.25% in A1C ($p<0.001$). There was a non-significant trend towards tobacco cessation.

Conclusion This is the first study on CV risk reduction in patients with inflammatory conditions in a community pharmacy setting. R_xIALTA provides evidence for the

Strengths and limitations of this study

- This is the first study to assess the effect of a pharmacist-led case finding and care on cardiovascular (CV) risk in patients with chronic inflammatory conditions in a community pharmacy setting.
- The pharmacist-led case finding and care enhanced access to CV risk assessment and care in a high-risk population that otherwise would not have their CV risk assessed.
- The pharmacist-led case finding and care (including prescribing and ordering laboratory tests) was associated with CV risk reduction and improvement in all the individual CV disease risk factors.

benefit of pharmacist care on global cardiovascular risk reduction as well as the individual cardiovascular risk factors in patients with inflammatory conditions.

Trial registration number NCT03152396.

INTRODUCTION

Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality worldwide and in Canada accounting for nearly one-third of the total deaths.^{1 2} The majority of CVD cases are caused by modifiable risk factors such as tobacco use, obesity, hypertension, hyperlipidaemia, diabetes and physical inactivity.³ Chronic inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis ankylosing spondylitis, gout, systemic lupus erythematosus and psoriasis, are also increasingly being recognised as independent risk factors for CVD.^{4–7} Indeed, it has been reported that the risk of myocardial infarction, heart failure and CV death among patients with chronic inflammatory disease is twofold to threefold greater than

in the general population.^{8–10} Such increased risk can be explained by the combined impact of systemic inflammation, burden of traditional CVD risk factors and impact of certain medications (eg, steroids, non-steroidal anti-inflammatories (NSAIDs), retinoids).^{5,6}

Despite being recommended by international guidelines,⁷ CV risk assessment has not been incorporated into many clinicians' daily routine.⁷ In fact, reports indicate that such assessments generally only exist in larger centres for non-rheumatology patients.^{11–13} Moreover, Keeling *et al* reported that most rheumatologists, who are the main caregivers for patients with these conditions, conducted suboptimal CV risk assessments.¹⁴ Unfortunately, this gap in care is not consistently absorbed by family physicians due to lack of recognition of CV risk in these patients and competing demands of other healthcare needs.⁷ Furthermore, many patients, especially those who are living in remote or rural areas, do not have access to family physicians.¹⁵ These facts, combined with the benefits of early identification after the diagnosis,¹⁶ highlight the need for new and innovative ways for assessing CV risk in this high-risk population.

Special considerations need to be taken into account when calculating CV risk in patients with chronic inflammatory diseases, as the 'classic' risk engines (such as Framingham¹⁷ might underestimate the overall risk,¹⁸ since they have not been adequately evaluated in this patient population.^{5,19} For example, those patients who might benefit from lipid-lowering agents may be categorised 'low risk' when using the Framingham risk engine.¹⁸ As such, it has been recommended to use a modified Framingham risk engine (multiply the overall risk by 1.5) in this patient population.²⁰ There is conflicting evidence in the literature regarding lipid panel measurements in patients with rheumatoid arthritis. Some studies reported that total cholesterol and LDL-cholesterol are significantly lower, while other studies reported that they are significantly higher in patients with rheumatoid arthritis when compared with the general population.^{21–23} Despite the variation, it is still recommended to treat patients with rheumatoid arthritis to general population lipid targets with consideration of risk modification, such as the European League Against Rheumatism recommendations that suggest multiplying the CV risk score by a factor of 1.5 in these patients.^{24,25}

Pharmacists are front line, accessible, primary healthcare professionals who see patients at risk/with chronic conditions more frequently than any other healthcare provider.²⁶ The efficacy of their interventions in chronic diseases including diabetes,²⁷ dyslipidaemia,²⁸ hypertension,^{29–32} heart failure³³ and CVD^{34–36} has been well demonstrated in the literature. Pharmacists can systematically identify patients at high risk of CVD,³⁶ help manage their condition, improve their medication use^{31,32,37} and assist them to achieve their treatment targets.^{27–32} In addition to clinical outcomes, pharmacist interventions are also associated with high levels of patient satisfaction, improved adherence to therapy and considerable cost

savings and efficient use of healthcare resources.^{31,32,38–40}

This evidence, coupled with their full scope of practice including prescribing and laboratory test monitoring, ideally position pharmacists to conduct CV risk assessment and management. Therefore, we conducted this study to determine the effect of a pharmacist-led intervention on CV risk in patients with chronic inflammatory diseases.

METHODS

R_xIALTA was a non-randomised prospective pre–post-intervention study that was conducted in 17 community pharmacies across Alberta, Canada (for a list of the participating pharmacies please see the acknowledgement section). We used a non-randomised design because our previous work in pharmacist-led CV risk reduction,³⁶ a 723 patient (those with diabetes, chronic kidney disease, established vascular disease or Framingham risk >20%) randomised trial demonstrated significant reductions in estimated cardiovascular risk, and it was felt unethical to randomise this underserved high-risk population to usual care.

Patients were included if they were adults (≥18 years of age) with a physician-diagnosed chronic inflammatory condition (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, gout, systemic lupus erythematosus or psoriasis) and had at least one uncontrolled risk factor (blood pressure (≥140/90 without diabetes; ≥130/80 with diabetes),⁴¹ LDL-cholesterol (>2.0 mmol/L),⁴² A1C (>7.0%)⁴³ or current tobacco use). We excluded patients if they were unwilling to participate/sign the consent form, unwilling or unable to participate in regular follow-up visits, pregnant or experiencing a disease exacerbation (this may be indicated by current treatment with high or tapering dose of steroids), since lipid panel is most accurately measured when inflammatory diseases are stable or in remission.⁵

Recruitment

Pharmacists and pharmacy staff used the following methods to identify potential patients: (1) Proactive case finding: patients with physician-diagnosed chronic inflammatory conditions were identified by reviewing prescriptions of diseasemodifying antirheumatic drugs, NSAIDs, immunosuppressants, gout medications, biologics (eg, adalimumab, infliximab, ustekinumab, ixekizumab, secukinumab) and/or topical drugs containing calcipotriol, methotrexate with a rheumatologist or a dermatologist prescriber; (2) Case finding via in-pharmacy posters and weekly fliers and (3) Case finding via bag stuffers with the above medications.

As part of routine care, pharmacists measured the blood pressure and checked the most recent laboratory test results for the identified patients (through the provincial electronic health record). They then checked whether patients met the inclusion criteria. The pharmacists explained the study to those who met the inclusion

criteria and invited them to take part. Patients who agreed to take part were asked to sign a written informed consent form. Once the signed written informed consent form was obtained the patients were enrolled in the study.

The patient's physician(s) received a letter from the pharmacist to inform them that the patient agreed to participate in this study.

Intervention

All enrolled patients received: (1) Patient assessment (blood pressure measurement according to Hypertension Canada guidelines,⁴¹ waist circumference, weight and height measurements), (2) Laboratory assessment of A1C, non-fasting lipid panel (total cholesterol, LDL-cholesterol and HDL-cholesterol) and kidney function and status (creatinine (and estimated glomerular filtration rate), random urine albumin to creatinine ratio), (3) Individualised CV risk assessment and education regarding this risk using a validated interactive online tool³⁶ that explains the individual's CV risk, the contribution of each risk factor to the overall risk and the impact of the intervention and controlling the risk factors on the overall CV risk (<https://www.epicore.ualberta.ca/epirisk/>), (4) Treatment recommendations, prescription adaptation and prescribing where necessary to meet guideline recommended targets. Pharmacists practised to their full scope (including prescribing medications and ordering and interpreting laboratory tests when needed), (5) Regular monthly follow-up for 6 months to check on patients' progress and provide ongoing care and motivation; and (6) Regular communication with the patient's physician(s) after each contact with the patient as per usual pharmacist practice.

Patient and public involvement

No patient involved

Outcomes

The primary outcome was the change in CV risk over a 6-month period. CV risk is defined as the risk for future CV events (coronary heart disease, stroke, peripheral arterial disease)^{7 8} as calculated by validated risk assessment equations. The CV risk was calculated using EPI-RISK Cardiovascular Risk Calculator (<https://www.epicore.ualberta.ca/epirisk/>). It was estimated using the Modified Framingham²⁰ risk assessment equation (Framingham risk score multiplied by 1.5) for patients who have chronic inflammatory conditions without other comorbidities. If the patient had other CV risk-modifying conditions (diabetes, previous vascular disease or chronic kidney disease), risk was calculated using the Modified Framingham²⁰ and the most appropriate risk assessment equation based on the patient's medical history. The UK Prospective Diabetes Study⁴⁴ risk assessment equation was used for those with diabetes, SMART risk assessment equation⁴⁵ was used for patients with previous vascular disease and Framingham¹⁷ risk assessment equation was used for the ones with chronic kidney disease. If the patient had

both chronic inflammatory conditions and other CV risk-modifying conditions, the risk was calculated using all the respective risk assessment equations, and the risk assessment equation estimating the highest risk was used.

The secondary outcomes were the change in individual risk factors (blood pressure (in patients with hypertension), LDL-cholesterol (in patients with dyslipidaemia), A1C (in patients with diabetes) and tobacco cessation (self-reported abstinence)) over a 6-month period.

Sample size and analytical plan

Sample size

Using the information from our previous pharmacist-led CV risk reduction trial, REACH³⁶ (Baseline CV risk (26.2%) and standard deviation (SD) (17.8)) and the




Figure 1 Study flow chart.

following assumptions of 80% power and alpha of 0.05, 89 patients were required to detect 21% risk reduction. The sample size was inflated to 100 to account for possible dropouts, lost to follow-up and withdrawals of consent.

Analytical plan

Analysis was performed by using R V.3.6.2 (Vienna, Austria; <https://www.R-project.org/>) and SAS V.9.4 software (SAS Institute).

Data were first screened to confirm that all the participating patients met the inclusion/exclusion criteria and provided informed consent. Once those conditions were confirmed, statistical analysis started.

Demographic information and clinical characteristics were analysed using descriptive statistics. Frequency (percentage) was used for categorical variables and mean (SD) for continuous variables. Statistical significance at the univariable level was assessed using χ^2 test or Fisher's exact test (when small frequencies present) for categorical variables, and t-test for continuous variables (assumption of statistics tests were checked ahead). The primary outcome was analysed by paired t-test. Multivariable linear mixed effect models were used to adjust for centre effect, age, sex and ethnicity. Secondary outcomes were analysed using paired t-test and χ^2 test as appropriate.

Trial and data management was performed by EPICORE Centre.

RESULTS

The study was launched in August 2017, and the last patient was enrolled in July 2019. Follow-up was completed in January 2020. We screened 126 patients, of those 103 were eligible. We enrolled 99 patients and 94 of them completed the study (figure 1). Demographic and clinical characteristics are presented in table 1. Mean age was 64 years (SD 14.8), approximately two-thirds (61%) of the participants were female and 86% were Caucasian. More than half (56%) had rheumatoid arthritis, 14% had psoriasis, 12% had psoriatic arthritis, 11% had gout, 6% had ankylosing spondylitis and 1% had systemic lupus erythematosus. Hypertension was the most commonly reported risk factor (47%), followed by dyslipidaemia (45%), diabetes (13%), atherosclerotic vascular events (angina, heart attack, stroke/TIA) (12%), current tobacco use (11%) and chronic kidney disease (9%). In addition, average body mass index was 28.2 (5.2) kg/m² and only 9% reported exercising for 30 min (or more) five or more times per week. Importantly, only 2% of participants reported that their CV risk was assessed by a healthcare provider before taking part in the study.

Estimated CV risk was reduced from 25% (SD 16.1) at baseline to 19.8% (SD 14.7) after 6 months. After adjusting for age, sex, ethnicity and centre effect, such reduction corresponded to a 24.5% relative risk reduction (6 (95% CI (4.6 to 7.4)) p<0.001) (figure 2). In patients with hypertension, significant reductions were observed

in systolic and diastolic blood pressure (table 2). Similarly, we noted reductions in LDL-cholesterol in patients with dyslipidaemia and A1C in those with diabetes (table 2). Participants' dietary habits were also improved (p=0.02), while exercise, alcohol and tobacco use were not significantly changed.

Pharmacist interventions are listed in figure 3. Medication/dose change was the most implemented intervention (30%), followed by lifestyle education and advice (27%), patient, family members and caregivers' education about the condition and prescribed treatment (22%), follow-up (12%), adherence assessment and improvement (7%) and referral to other healthcare providers (2%). There were very minimal adverse events reported during the study.

DISCUSSION

Chronic inflammatory conditions increase patient's risk for CV events; however, these patients are often not receiving CV risk assessment or treatment. We hypothesised that community pharmacists could proactively and systematically screen for chronic inflammatory diseases (because of the unique medications used in these conditions), and then manage their CV risk factors. We found that a pharmacist-led care reduced the risk of major CV events by 24.5% (p<0.001) over a 6-month period. The intervention was also associated with reductions in blood pressure, LDL-cholesterol and A1C. Such improvements are related to the following pharmacist activities: medication/dose changes, lifestyle education and advice, patient, family members and caregivers' education about the condition and prescribed treatment, follow-up, adherence assessment and improvement and referral to other healthcare providers.

Our findings are consistent with the findings of the R_xEACH study, which evaluated the impact of pharmacist intervention (assessment, prescribing and follow-up) on CV risk in patients at high risk for CVD (patients with diabetes, chronic kidney disease, established vascular disease or Framingham risk >20%). R_xEACH reported that such intervention was associated with CV risk reduction as well as improvements in all individual risk factors.³⁶

Our findings are also consistent with the findings of Semb *et al* who reported significant CV risk reduction when a CV risk factor (lipids) was managed appropriately.²¹ They also highlight the importance of pharmacist prescribing, as 'medication/dose change' was the most implemented intervention. This intervention would have not been possible without having independent prescriptive authority. These findings are supported by the findings of Al Hamarneh *et al* and Wubben and Vivian who reported that better outcomes were achieved when pharmacists had prescriptive authority.^{46 47}

This study is not without limitations. As described above, the study was not a randomised controlled trial, due to ethical concerns of randomising this high-risk underserved population to usual care after proving that

Table 1 Baseline demographic and clinical characteristics

Characteristic		Frequency	Percentage
Sex	Female	60	61
Ethnicity	Aboriginal/first nations	3	3
	Black	2	2
	Caucasian	85	86
	Hispanic	2	2
	South-Asian	1	1
	Other Asian	6	6
Inflammatory conditions	RA	55	56
	Psoriasis	14	14
	PsA	12	12
	Gout	11	11
	AS	6	6
	SLE	1	1
Risk factors	Hypertension	47	47
	Dyslipidaemia	45	45
	Diabetes	13	13
	Atherosclerotic vascular events	12	12
	Current tobacco use	11	11
	CKD	9	9
Exercise	Very active	9	9
	Moderately active	39	39
	No exercise additional to ordinary daily living	49	50
	Not reported	2	2
Alcohol use	None	38	38
	1–2/day	40	41
	>2 drinks/day	14	14
	1–3 drinks/week	5	5
	Not reported	2	2
Dietary habits	No specific diet	85	86
	Low sugar	3	3
	Low salt	7	7
	Low saturated fat	1	1
	High fruit/vegetables	6	6
	Other	2	2
Characteristic		Mean	SD
Age	Age, years	64	14.8
Physical and lab assessment	BMI, kg/m ²	28.2	5.2
	Systolic BP, mm Hg	136.6	15.7
	Diastolic BP, mm Hg	81.8	11.4
	Total cholesterol, mmol/L	4.8	1.3
	HDL-cholesterol, mmol/L	1.4	0.5
	LDL-cholesterol, mmol/L	2.6	1.1
	A1C, %	8.3	1.1
	eGFR, ml/min/1.73 m ²	76.6	18.5
	ACR, mg/mmol	154.7 (Median)	77.5–231.8 (IQR)

A1C, Glycated Hemoglobin; ACR, albumin to creatinine ratio; AS, ankylosing spondylitis; BMI, body mass index; BP, Blood pressure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.




Figure 2 Change in estimated CV risk over time. CV, cardiovascular.

the intervention is effective. We acknowledge that this reduces causal inference, however, the findings of this study are similar to the randomised REACH study.³⁶ Since the 6-month follow-up period can be considered relatively short; it is possible that the effects of the intervention could be short lived. It is also possible, however, that greater improvements leading to larger CV risk reduction could have been observed with a longer follow-up period. Pharmacists who provided the intervention also conducted the assessment and entered the information into the study online system where CV risk was calculated. This could have introduced bias; however, the study team monitored study sites against source documents to ensure accuracy. The fact that adverse events were self-reported could have led to under-reporting.

Our findings, combined with the fact that the risk of myocardial infarction, heart failure and CV death among

patients with chronic inflammatory diseases is much higher than the general population,^{8–10} highlight the importance of focusing on the patient as a whole, rather than only focusing on their acute complaints.

It is noteworthy that only 2% of our participants had their CV risk assessed before taking part in the study. This is consistent with the literature, as it has been reported that the levels of awareness and perceived risk of CVD is low in this patient population.⁴⁸ Gaps in care have also been reported when it comes to CV risk assessment.^{7 12–14} This also highlights the importance of a systematic and proactive approach towards case finding by pharmacists—as many patients would not know to ask for CV risk assessment. This is a unique feature of involving community pharmacists—an approach which we have used successfully in a number of areas.^{28 36 49}

Table 2 Changes in individual risk factors

Risk factor	Baseline	6 months	Difference (95% CI)	P value
Systolic BP (n=47)	138.4 (17.9)	127.7 (10.3)	10.7 (10 to 12.6)	<0.001
Diastolic BP (n=47)	80.2 (13)	77.3 (10.1)	2.9 (1.9 to 3.9)	<0.001
Total Cholesterol (n=45)	5 (1.4)	4.6 (1.3)	0.4 (0.3 to 0.4)	<0.001
LDL-cholesterol (n=45)	2.8 (1.2)	2.5 (1.1)	0.3 (0.3 to 0.4)	<0.001
HDL-cholesterol (n=45)	1.4 (0.5)	1.5 (0.5)	0.1 (0.1 to 0.2)	<0.001
A1C (n=13)	8.3 (1.1)	7.1 (1)	1.2 (0.6 to 1.9)	<0.001
BMI	28.2 (5.2)	28.3 (5.3)	0.1 (-0.2 to 0.1)	0.5
Tobacco use (proportion)	10.3	5.2	N/A	0.3

A1C, Glycated Hemoglobin; BMI, body mass index; BP, Blood Pressure; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; N/A, not available.




Figure 3 Pharmacist interventions.

R_xIALTA findings add to the high-level evidence of effective pharmacist prescribing interventions in improving CV risk and individual CVD risk factors.^{36–49} Such high-level evidence should encourage policy makers to broaden the scope of practice for pharmacists and pharmacy professional organisations to implement those interventions on a larger scale to seize the opportunity to enhance patient care.

To our knowledge, this is the first study to assess the effect of a pharmacist-led case finding and care on CV risk in patients with chronic inflammatory conditions in a community pharmacy setting. We have demonstrated that pharmacist-led intervention (including prescribing) improved CV risk as well as the individual CVD risk factors. Pharmacists also improved the access to care in a high-risk population that otherwise would not have their CV risk assessed. Implementing this on a wider scale could help addressing one of the world's major public health challenges.

Author affiliations

¹EPICORE Centre, University of Alberta, Edmonton, Alberta, Canada

²Faculty of Pharmacy, University of Otago, Dunedin, New Zealand

³Medicine, University of Alberta, Edmonton, Alberta, Canada

⁴Rheumatology, University of Alberta, Edmonton, Alberta, Canada

⁵Foothills Medical Centre, Calgary, Alberta, Canada

⁶Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada

Acknowledgements None of this could have taken place without the dedication and caring of the R_xIALTA investigators, listed in descending order

of recruitment: Nader Hammoud (Shoppers Drug Mart #2326, Calgary), Nataliya Posudwvska (Calgary Co-op, Calgary), Rick Siemens (London Drugs #38, Lethbridge), Dixie Richardson (Safeway Pharmacy, Edmonton), Aileen Coutts (Calgary Co-op, Calgary), Jan Messiha (Calgary Co-op, Calgary), Farzana Sharif (Calgary Co-op, Calgary), Pegah Manzoori (Calgary Co-op, Calgary), Maria James (Calgary Co-op, Calgary), Jack Dhaliwal (Calgary Co-op, Calgary), Derek Durocher (Shoppers Drug Mart #313, Edmonton), Leanna St. Onge, Otti Gohrbandt and Chelsey Collinge (Co-op Pharmacy, Rocky Mountain House), Aila Omar (Co-op Pharmacy, Edmonton), Diane Lazarko-Gamache (Calgary Co-op, Calgary), Sonal Ijner (Calgary Co-op, Calgary), Carlene Olyksen, Jelena Okuka (Meridian Pharmacy, Stony Plain), Murtaza Hassanali (Shoppers Drug Mart #371, Edmonton), Penny and Fausta (Penny and Fausta Pharmacy, Calgary).

Contributors Substantial contribution to study conception and design: YNAH, RG, SK, CM, AM and RT. Substantial contribution to data collection: YNAA, AM and RT. Substantial contribution to data analysis and interpretation: YNAH and RT. Drafting the article or revising it critically: YNAH, RG, SK, CM, AM and RT. Final approval of the submitted version: YNAH, RG, SK, CM, AM and RT.

Funding We would like to acknowledge the generous support of the funder of R_xIALTA: Canadian Initiative for Outcomes in Rheumatology cAre (CIORA) (grant number: 2015–001).

Disclaimer Our funder did not have any role in the study design, collection, analysis, interpretation of the data, writing the report and the decision to submit for publication. We would like to acknowledge the support of the Consultation and Research Services Platform at The Alberta' SPOR SUPPORT Unit in Data management and statistical services (Grant number N/A).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval R_xIALTA was approved by the Health Research Ethics Board of the University of Alberta (Pro00072858).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. Data will be available on reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Yazid N Al Hamarneh <http://orcid.org/0000-0003-3984-3542>

REFERENCES

- 1 WHO. Cardiovascular diseases, 2017. Available: <http://www.who.int/mediacentre/factsheets/fs317/en/> [Accessed June 9, 2020].
- 2 Government of Canada. Report from the Canadian chronic disease surveillance system: heart disease in Canada, 2018, 2018. Available: <https://www.canada.ca/en/public-health/services/publications/diseases-conditions/report-heart-disease-Canada-2018.html> [Accessed June 9, 2020].
- 3 The Arthritis Society. Arthritis in Canada, facts and figures, 2020. Available: <https://arthritis.ca/about-arthritis/what-is-arthritis/arthritis-facts-and-figures> [Accessed June 9, 2020].
- 4 Nurmohamed MT. Cardiovascular risk in rheumatoid arthritis. *Autoimmun Rev* 2009;8:663–7.
- 5 Peters MJL, Symmons DPM, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. *Ann Rheum Dis* 2010;69:325–31.
- 6 Semb AG, Rollefstad S, van Riel P, et al. Cardiovascular disease assessment in rheumatoid arthritis: a guide to translating knowledge of cardiovascular risk into clinical practice. *Ann Rheum Dis* 2014;73:1284–8.
- 7 Schieir O, Tosevski C, Glazier RH, et al. Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis. *Ann Rheum Dis* 2017;76:1396–404.
- 8 Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. *Arthritis Rheum* 2005;52:402–11.
- 9 Nicola PJ, Maradit-Kremers H, Roger VL, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. *Arthritis Rheum* 2005;52:412–20.
- 10 Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. *Arthritis Rheum* 2005;52:722–32.
- 11 Mills M, Loney P, Jamieson E, et al. A primary care cardiovascular risk reduction clinic in Canada was more effective and no more expensive than usual on-demand primary care—a randomised controlled trial. *Health Soc Care Community* 2010;18:30–40.
- 12 Woodward A, Wallymahmed M, Wilding J, et al. Successful cardiovascular risk reduction in type 2 diabetes by nurse-led care using an open clinical algorithm. *Diabet Med* 2006;23:780–7.
- 13 Woodward A, Wallymahmed M, Wilding J, et al. Improved glycaemic control—an unintended benefit of a nurse-led cardiovascular risk reduction clinic. *Diabet Med* 2005;22:1272–4.
- 14 Keeling SO, Teo M, Fung D. Lack of cardiovascular risk assessment in inflammatory arthritis and systemic lupus erythematosus patients at a tertiary care center. *Clin Rheumatol* 2011;30:1311–7.
- 15 Canadian Institute for Health Information. Physicians in Canada, 2018, 2019. Available: <https://www.cihi.ca/sites/default/files/document/physicians-in-canada-2018.pdf> [Accessed June 9, 2020].
- 16 Kremers HM, Crowson CS, Therneau TM, et al. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. *Arthritis Rheum* 2008;58:2268–74.
- 17 D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. *Circulation* 2008;117:743–53.
- 18 Arts EEA, Popa C, Den Broeder AA, et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. *Ann Rheum Dis* 2015;74:668–74.
- 19 Chung CP, Oeser A, Avalos I, et al. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. *Arthritis Res Ther* 2006;8:R186.
- 20 Tournadre A, Mathieu S, Soubrier M. Managing cardiovascular risk in patients with inflammatory arthritis: practical considerations. *Ther Adv Musculoskelet Dis* 2016;8:180–91.
- 21 Semb AG, Kvien TK, DeMicco DA, et al. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. *Arthritis Rheum* 2012;64:2836–46.
- 22 Liao KP, Cai T, Gainer VS, et al. Lipid and lipoprotein levels and trend in rheumatoid arthritis compared to the general population. *Arthritis Care Res* 2013;65:2046–50.
- 23 Liao KP, Liu J, Lu B, et al. Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients. *Arthritis Rheumatol* 2015;67:2004–10.
- 24 Peters MJL, Symmons DPM, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. *Ann Rheum Dis* 2010;69:325–31.
- 25 Rollefstad S, Kvien TK, Holme I, et al. Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic. *Ann Rheum Dis* 2013;72:1968–74.
- 26 Shiu JR, Simpson SH, Johnson JA. Quantifying opportunities to affect diabetes management in the community. *Can Pharm J* 2006;139:37–8.
- 27 Rothman RL, Malone R, Bryant B, et al. A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. *Am J Med* 2005;118:276–84.
- 28 Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the study of cardiovascular risk intervention by pharmacists (SCRIP). *Arch Intern Med* 2002;162:1149–55.
- 29 Carter BL, Bergus GR, Dawson JD, et al. A cluster randomized trial to evaluate physician/pharmacist collaboration to improve blood pressure control. *J Clin Hypertens* 2008;10:260–71.
- 30 McLean DL, McAlister FA, Johnson JA, et al. A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN). *Arch Intern Med* 2008;168:2355–61.
- 31 Blenkinsopp A, Phelan M, Bourne J, et al. Extended adherence support by community pharmacists for patients with hypertension: a randomised controlled trial. *International Journal of Pharmacy Practice* 2011;8:165–75.
- 32 Wang J, Wu J, Yang J, et al. Effects of pharmaceutical care interventions on blood pressure and medication adherence of patients with primary hypertension in China. *Clin Res Regul Aff* 2011;28:1–6.
- 33 Gattis WA, Hasselblad V, Whellan DJ, et al. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the pharmacist in heart failure assessment recommendation and monitoring (pharm) study. *Arch Intern Med* 1999;159:1939–45.
- 34 Taveira TH, Wu W-C, Martin OJ, et al. Pharmacist-Led cardiac risk reduction model. *Prev Cardiol* 2006;9:202–8.
- 35 Santschi V, Chioloro A, Burnand B, et al. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. *Arch Intern Med* 2011;171:1441–53.
- 36 Tsuyuki RT, Al Hamarneh YN, Jones CA, et al. The effectiveness of pharmacist interventions on cardiovascular risk. *J Am Coll Cardiol* 2016;67:2846–54.
- 37 Murray MD, Ritchey ME, Wu J, et al. Effect of a pharmacist on adverse drug events and medication errors in outpatients with cardiovascular disease. *Arch Intern Med* 2009;169:757.
- 38 Marra C, Johnston K, Santschi V, et al. Cost-Effectiveness of pharmacist care for managing hypertension in Canada. *Can Pharm J* 2017;150:184–97.
- 39 Al Hamarneh YN, Johnston K, Marra CA, et al. Pharmacist prescribing and care improves cardiovascular risk, but is it cost-effective? A cost-effectiveness analysis of the R_xEACH study. *Can Pharm J* 2019;152:257–66.
- 40 Al Hamarneh YN, Lamb S, Donald M, et al. Pharmacist prescribing and care improves cardiovascular risk, but what do patients think? A substudy of the R_xEACH study. *Can Pharm J* 2018;151:223–7.
- 41 Nerenberg KA, Zarnke KB, Leung AA, et al. Hypertension Canada's 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. *Can J Cardiol* 2018;34:506–25.
- 42 Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian cardiovascular Society guidelines for the management of

- dyslipidemia for the prevention of cardiovascular disease in the adult. *Can J Cardiol* 2016;32:1263–82.
- 43 Canada D, Canada D. Clinical practice guidelines for the prevention and management of diabetes in Canada. *Canadian Journal of Diabetes* 2018;2018:S1–326.
- 44 Stevens RJ, Kothari V, Adler AI, *et al*. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). *Clin Sci* 2001;101:671–9.
- 45 Dorresteijn JAN, Visseren FLJ, Wassink AMJ, *et al*. Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the smart risk score. *Heart* 2013;99:866–72.
- 46 Al Hamarneh YN, Hemmelgarn BR, Hassan I, *et al*. The Effectiveness of Pharmacist Interventions on Cardiovascular Risk in Adult Patients with Type 2 Diabetes: The Multicentre Randomized Controlled R_xEACH Trial. *Can J Diabetes* 2017;41:580–6.
- 47 Wubben DP, Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. *Pharmacotherapy* 2008;28:421–36.
- 48 Ghosh-Swaby OR, Kuriya B. Awareness and perceived risk of cardiovascular disease among individuals living with rheumatoid arthritis is low: results of a systematic literature review. *Arthritis Res Ther* 2019;21:33–9.
- 49 Tsuyuki RT, Houle SKD, Charrois TL, *et al*. Randomized trial of the effect of pharmacist prescribing on improving blood pressure in the community: the Alberta clinical trial in optimizing hypertension (RxACTION). *Circulation* 2015;132:93–100.